Ascendis Pharma A (ASND) Non-Current Assets (2012 - 2026)
Ascendis Pharma A (ASND) posted Non-Current Assets of $1.0 billion for Q1 2026, up 26228.31% sequentially from -$3.9 million in Q4 2025, and up 600.59% YoY from $147.2 million in Q1 2025.
Ascendis Pharma A (ASND) Non-Current Assets (2012 - 2026) Analysis & Trends
Ascendis Pharma A has reported Non-Current Assets for 15 years, with the latest figure at $1.0 billion in Q1 2026.
- Quarterly Non-Current Assets rose 600.59% year-over-year to $1.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 600.59% YoY) and the FY2025 annual result came in at $225.3 million, up 81.29% from the prior year.
- Non-Current Assets rose to $1.0 billion in Q1 2026 per ASND's latest filing, from -$3.9 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $1.0 billion in Q1 2026 and troughed at -$3.9 million in Q4 2025.
- A 5-year average of $197.8 million and a median of $152.7 million in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2025 and 2026: Non-Current Assets tumbled 864.46% in 2025, then surged 600.59% in 2026.
- Over 5 years, Non-Current Assets stood at $136.6 million in 2022, then decreased by 9.4% to $123.8 million in 2023, then tumbled by 100.33% to -$409272.0 in 2024, then sank by 864.46% to -$3.9 million in 2025, then soared by 26228.31% to $1.0 billion in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $1.0 billion, -$3.9 million, and $160.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | 1.03 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.03 Bn |
| Dec 31, 2025 | -3.95 Mn |
| Sep 30, 2025 | 160.12 Mn |
| Jun 30, 2025 | 152.75 Mn |
| Mar 31, 2025 | 147.21 Mn |
| Dec 31, 2024 | -409,272.04 |
| Sep 30, 2024 | 131.83 Mn |
| Jun 30, 2024 | 141.05 Mn |
| Mar 31, 2024 | 150.34 Mn |
| Dec 31, 2023 | 123.79 Mn |
| Sep 30, 2023 | 152.72 Mn |
| Jun 30, 2023 | 159.14 Mn |
| Mar 31, 2023 | 167.90 Mn |
| Dec 31, 2022 | 136.63 Mn |
| Sep 30, 2022 | 195.12 Mn |
| Jun 30, 2022 | 229.14 Mn |
| Mar 31, 2022 | 287.51 Mn |
| Dec 31, 2021 | 150.23 Mn |
| Sep 30, 2021 | 293.22 Mn |
| Jun 30, 2021 | 322.26 Mn |